In middle-aged male mice, an earlier loss of new tumor-fighting immune cells lined up with weaker melanoma control

What the research found

Massachusetts General Hospital researchers reported in Nature Aging that middle-aged male mice controlled implanted melanoma less well than middle-aged female mice, and that the gap depended on CD8 immune cells. Males lost naive CD8 cells earlier. Some of those cells shifted into a lookalike of experienced immune cells without ever meeting their target, and that shift lined up with a weaker response to the tumor. Human blood data the authors checked also suggested an age-related drop in naive CD8 cells that was larger in males. Taking the thymus out early erased the female advantage. In male mice, lowering testicular hormone signals rebuilt naive CD8 counts and improved tumor control. This is a mouse study. It does not show that hormone suppression treats cancer in people. That kind of care is clinician-only. Not medical advice.

Evidence level: Animal study. Results in animals or cells often don't carry over to people.

Read the original at Lifespan.io